---
title: "Aura Biosciences, Inc. (AURA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AURA.US.md"
symbol: "AURA.US"
name: "Aura Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T16:47:21.348Z"
locales:
  - [en](https://longbridge.com/en/quote/AURA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AURA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AURA.US.md)
---

# Aura Biosciences, Inc. (AURA.US)

## Company Overview

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.aurabiosciences.com](https://www.aurabiosciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.25 | 415 | - | - | - |
| PB | 7.60 | 378 | 3.18 | 2.42 | 2.19 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 83% |
| Overweight | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.57 |
| Highest Target | 24.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AURA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AURA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AURA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AURA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**